Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Account Payables: 2014-2025

Historic Change in Account Payables for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to -$1.4 million.

  • KalVista Pharmaceuticals' Change in Account Payables fell 122.83% to -$1.4 million in Q2 2025 from the same period last year, while for Apr 2025 it was $348,000, marking a year-over-year decrease of 91.94%. This contributed to the annual value of -$5.0 million for FY2025, which is 215.07% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Change in Account Payables stood at -$1.4 million for Q2 2025, which was up 76.25% from -$5.9 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' 5-year Change in Account Payables high stood at $6.1 million for Q2 2024, and its period low was -$5.9 million during Q4 2024.
  • Its 3-year average for Change in Account Payables is -$204,286, with a median of $55,000 in 2023.
  • Within the past 5 years, the most significant YoY rise in KalVista Pharmaceuticals' Change in Account Payables was 1,290.74% (2024), while the steepest drop was 10,754.55% (2024).
  • KalVista Pharmaceuticals' Change in Account Payables (Quarterly) stood at $55,000 in 2023, then crashed by 10,754.55% to -$5.9 million in 2024, then tumbled by 122.83% to -$1.4 million in 2025.
  • Its Change in Account Payables stands at -$1.4 million for Q2 2025, versus -$5.9 million for Q4 2024 and $1.5 million for Q3 2024.